Hotline from EuroPCR 2025 - Five-year outcomes from the Evolut low risk TAVR bicuspid study

Simon Redwood and John Forrest exchange insights on the Evolut Low Risk Bicuspid Study, which explores transcatheter aortic valve replacement (TAVR) in younger, low-risk patients with bicuspid aortic valves—an anatomy often excluded from earlier trials.

They review the trial design, patient characteristics, and results, comparing outcomes with those of the main Evolut Low Risk study. Early findings suggest that Evolut performs at least as well in bicuspid valves as in tricuspid ones—perhaps even better—though extended follow-up will be key to confirm durability and safety.

The conversation also touches on valve thrombosis and the broader implications for treating a younger patient population.

Watch the exchange to learn more about the future of TAVR in bicuspid aortic stenosis.

This interview was filmed at EuroPCR 2025: see more videos here.